Welcome to our dedicated page for Tevogen SEC filings (Ticker: TVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tevogen Bio Holdings Inc. (TVGN) SEC filings page on Stock Titan aggregates the company’s official disclosures from the U.S. Securities and Exchange Commission, offering a structured view into this clinical-stage biotechnology issuer’s regulatory record. As a Nasdaq-listed company, Tevogen files periodic reports and current reports that detail its financial performance, operating strategy, and material events.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, management’s discussion and analysis, and commentary on Tevogen’s capital-efficient, cost-disciplined business model. For a company focused on precision T cell therapies and AI-enabled drug discovery, these filings provide context on research and development spending, general and administrative expenses, and non-GAAP measures such as adjusted loss from operations that Tevogen uses to describe operational performance.
Current reports on Form 8-K capture significant events, including listing and compliance matters. For example, Tevogen disclosed via Form 8-K that it received a Nasdaq notice regarding non-compliance with the $1.00 per share minimum bid price requirement, outlining the applicable compliance period and potential paths to regain compliance. Such filings help investors understand listing status and associated timelines.
The filings page also offers access to information related to equity structure, warrants, and other securities, as well as any proxy materials and, where applicable, insider transaction reports on Form 4. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as changes in operating loss, capital structure, or risk disclosures. Real-time updates from EDGAR ensure that new TVGN filings, from 10-Qs to 8-Ks, appear promptly with accessible explanations for investors analyzing Tevogen’s financial and regulatory trajectory.
Patton Curtis L. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Curtis L. Patton received a grant of 40,000 shares of restricted common stock under the company’s 2024 Omnibus Incentive Plan. The award vests in three equal installments, each tied to both a service requirement and revenue milestones of $50 million, $100 million, and $150 million of aggregate revenue since the grant date. Following this grant, Patton directly holds 64,192 shares of common stock.
Goh Keow Lin reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Goh Keow Lin received a grant of 40,000 shares of restricted common stock under the 2024 Omnibus Incentive Plan. The award vests in three equal installments upon the earlier of specified anniversaries of the grant date and the company reaching aggregate revenue milestones of $50 million, $100 million, and $150 million, subject to continued service. Following this grant, the director holds 48,678 common shares directly.
Feike Jeffrey L. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Jeffrey L. Feike received a grant of 40,000 shares of restricted common stock at $0.00 per share under the 2024 Omnibus Incentive Plan. The award vests in three equal installments tied to service-based anniversaries and aggregate revenue thresholds of $50 million, $100 million, and $150 million since the grant date. Following this grant, Feike directly holds 56,435 common shares.
Desai Kirti reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. granted its Chief Financial Officer, Kirti Desai, 40,000 shares of restricted common stock at $0.00 per share under the 2024 Omnibus Incentive Plan. The award vests in three equal installments upon specified combinations of service anniversaries and aggregate revenue targets of $50 million, $100 million, and $150 million, subject to continued service. Following this grant, Desai directly holds 242,983 shares of common stock.
Tevogen Bio Holdings Inc. registers up to 375,000 shares of common stock for resale by a selling stockholder. This prospectus covers resale, from time to time, by the identified Selling Stockholder of up to 375,000 shares issuable upon exercise of Pre-Funded Warrants issued in May 2026. The company is not selling any shares hereunder and will receive no proceeds from resale; the issuer will receive the net proceeds only if the Pre-Funded Warrants are exercised for cash, which have an aggregate exercise price of $37.50. The prospectus notes a Beneficial Ownership Limitation of 9.99% (adjustable to 19.99% with notice), and states 4,219,343 shares outstanding as of June 11, 2026.
Tevogen Bio Holdings Inc. filed a shelf prospectus to register for resale up to 375,000 shares of common stock issuable upon exercise of pre-funded warrants held by The Patel Family, LLP. The company will not receive proceeds from secondary sales; it will receive proceeds only if the Pre-Funded Warrants are exercised for cash (aggregate exercise price $37.50 stated). Shares outstanding were 4,219,343 as of June 11, 2026. The Patel Family currently holds shares and certain convertible/preferred rights such that the 375,000-share registration represents a potential 11.25% beneficial interest based on the disclosed outstanding shares. The Pre-Funded Warrants include a Beneficial Ownership Limitation of 9.99%, adjustable up to 19.99% with written notice (effective after the 61st day). Sales may occur through various methods described in the "Plan of Distribution."
Tevogen Bio Holdings Inc. reported a Q1 2026 net loss of $5.4M, improved from $10.4M a year earlier, mainly due to sharply lower general and administrative stock-based compensation. Operating expenses fell to $5.4M from $10.4M, with research and development relatively stable around $3.1M.
The company had cash of $0.7M as of March 31, 2026 and used $2.7M in operating cash flow, funded by draws on a related-party loan facility and at-the-market stock sales. Management expects existing cash, a $14.0M undrawn loan capacity, a remaining $7.0M grant commitment, and $3.0M PIPE warrant proceeds in May 2026 to support operations for at least 12 months, but does not plan to start new clinical trials until further funding is raised.
The balance sheet shows a stockholders’ deficit of $9.8M and total liabilities of $14.8M, including $6.4M outstanding under the loan and $1.7M of notes payable that are in default but carry no additional default payments. During the quarter the company completed a 1-for-50 reverse stock split and ended with 4,168,705 common shares outstanding. Subsequent events include a private placement of prefunded warrants for 375,000 shares raising about $3.0M, and Nasdaq notices that its market value of listed and publicly held shares has fallen below continued listing thresholds, giving it until mid-October 2026 to regain compliance.
Tevogen Bio Holdings Inc. filed Amendment No. 1 to its 2025 annual report to add Part III information that would otherwise have appeared in a proxy statement, and to update the cover page and exhibit list. The amendment does not update financial results.
The filing describes a staggered six‑member board, an independent audit committee with an audit committee financial expert, and a code of business conduct and insider trading policy. It details 2025 executive pay, including $10.4 million in total compensation for CEO Ryan Saadi driven largely by equity grants, plus long‑dated restricted stock and RSU awards for senior executives.
The amendment also discloses that Saadi beneficially owns 59.45% of outstanding common stock as of April 28, 2026, and that all directors and executives as a group hold 67.91%. Extensive related‑party arrangements with The Patel Family, LLP and affiliates are outlined, including preferred stock financings, a $36 million credit facility, consulting fees, a $2 million grant with additional commitments, and manufacturing services. KPMG’s audit fees totaled $587,000 for 2025.
Tevogen Bio Holdings Inc. has been notified by Nasdaq that it no longer meets two key Nasdaq Global Market listing standards tied to market value. Nasdaq found the company was below the $50 million minimum market value of listed securities and the $15 million minimum market value of publicly held shares for 30 consecutive business days. The stock remains listed for now, and Tevogen has 180 days, until October 13–14, 2026, to regain compliance by maintaining required market values for at least 10 consecutive business days. The company will monitor its market value and may consider actions, including a potential transfer to the Nasdaq Capital Market, but it cannot assure it will regain or maintain compliance.